title: [Three cases of secondary acute myeloid leukemia after long-term treatment with oral etoposide].
abstract: Three cases of secondary acute myeloid leukemia (AML) that developed after long term treatment with oral etoposide were reported. Case 1 was a 72-year-old male in whom small cell lung cancer was diagnosed in January 1987. He developed AML (M4) in February 1993 after long-term treatment with oral etoposide (total dose 14,650 mg) t(9; 11) (p21; q23) with rearrangement of MLL genes was recognized. Case 2 was a 68-year-old female non-Hodgkin's lymphoma (NHL) was diagnosed in February 1989. AML (M4Eo) with inv(16) (p13q22) developed in March 1994 after long-term treatment with oral etoposide (total dose 5,100 mg). Case 3 was a 39-year-old male in whom NHL was diagnosed in January 1991. He developed AML(M2) with t(11; 19) (q23; p13) in May 1994 after long-term treatment with oral etoposide (total dose 20,450 mg). These three cases suggest that long-term treatment with oral etoposide may be associated with a risk of developing a secondary AML in patient with malignancies.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Kikuta
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Sumikuma
authors.forename: Y
authors.initials: Y
authors.lastname: Sudo
authors.forename: N
authors.initials: N
authors.lastname: Yamagata
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: T
authors.initials: T
authors.lastname: Hatta
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008175:Lung Neoplasms / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide